Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood

A Pediatric Oncology Group study

M. L. Bernstein, V. M. Whitehead, S. Devine, H. Grier, F. Kung, J. Krischer, Z. Dreyer, B. Bell, V. Land, G. R. Buchanan, C. Pratt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Ifosfamide has previously been shown to be active as a single agent and in combination with doxorubicin, etoposide, and teniposide in pediatric solid tumors and adult acute leukemia. The authors performed a dose-escalation trial of ifosfamide with a fixed dosage of etoposide, with mesna uroprotection, in children with multiply recurrent acute leukemia. Methods. Chemotherapy was administered daily for 5 days. Etoposide 100 mg/m2 was followed by ifosfamide at an initial dosage of 1.6 g/m2. The ifosfamide was escalated in 20% increments to the maximum tolerated dosage in cohorts of three patients. Mesna 400 mg/m2 was given immediately before the ifosfamide and then at 3 and 6 hours after ifosfamide in the initial patients. Subsequent patients were treated with mesna 400 mg/m2 just before ifosfamide, and then every 2 hours to a total dosage equal to the ifosfamide dosage. Results. Forty-four heavily pretreated patients were entered on study. Forty were evaluable for toxicity and 36 for response as well. The maximum tolerated dosage of ifosfamide was 4.0 g/m2/d for 5 days (20 g/m2/course). Overall, 10 patients achieved complete remission, and 3 achieved partial remission. Remissions were brief, although four patients went on to bone marrow transplant while in remission. One patient is still alive. Conclusions. The combination of etoposide and ifosfamide with mesna uroprotection showed promising activity in children with multiply recurrent acute leukemia.

Original languageEnglish (US)
Pages (from-to)1790-1794
Number of pages5
JournalCancer
Volume72
Issue number5
StatePublished - 1993

Fingerprint

Mesna
Ifosfamide
Etoposide
Leukemia
Pediatrics
Teniposide
Doxorubicin
Bone Marrow

Keywords

  • chemotherapy
  • etoposide
  • ifosfamide
  • pediatric oncology
  • recurrent acute leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bernstein, M. L., Whitehead, V. M., Devine, S., Grier, H., Kung, F., Krischer, J., ... Pratt, C. (1993). Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood: A Pediatric Oncology Group study. Cancer, 72(5), 1790-1794.

Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood : A Pediatric Oncology Group study. / Bernstein, M. L.; Whitehead, V. M.; Devine, S.; Grier, H.; Kung, F.; Krischer, J.; Dreyer, Z.; Bell, B.; Land, V.; Buchanan, G. R.; Pratt, C.

In: Cancer, Vol. 72, No. 5, 1993, p. 1790-1794.

Research output: Contribution to journalArticle

Bernstein, ML, Whitehead, VM, Devine, S, Grier, H, Kung, F, Krischer, J, Dreyer, Z, Bell, B, Land, V, Buchanan, GR & Pratt, C 1993, 'Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood: A Pediatric Oncology Group study', Cancer, vol. 72, no. 5, pp. 1790-1794.
Bernstein ML, Whitehead VM, Devine S, Grier H, Kung F, Krischer J et al. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood: A Pediatric Oncology Group study. Cancer. 1993;72(5):1790-1794.
Bernstein, M. L. ; Whitehead, V. M. ; Devine, S. ; Grier, H. ; Kung, F. ; Krischer, J. ; Dreyer, Z. ; Bell, B. ; Land, V. ; Buchanan, G. R. ; Pratt, C. / Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood : A Pediatric Oncology Group study. In: Cancer. 1993 ; Vol. 72, No. 5. pp. 1790-1794.
@article{2147ce56ac1441b4b1311f4447f64475,
title = "Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood: A Pediatric Oncology Group study",
abstract = "Background. Ifosfamide has previously been shown to be active as a single agent and in combination with doxorubicin, etoposide, and teniposide in pediatric solid tumors and adult acute leukemia. The authors performed a dose-escalation trial of ifosfamide with a fixed dosage of etoposide, with mesna uroprotection, in children with multiply recurrent acute leukemia. Methods. Chemotherapy was administered daily for 5 days. Etoposide 100 mg/m2 was followed by ifosfamide at an initial dosage of 1.6 g/m2. The ifosfamide was escalated in 20{\%} increments to the maximum tolerated dosage in cohorts of three patients. Mesna 400 mg/m2 was given immediately before the ifosfamide and then at 3 and 6 hours after ifosfamide in the initial patients. Subsequent patients were treated with mesna 400 mg/m2 just before ifosfamide, and then every 2 hours to a total dosage equal to the ifosfamide dosage. Results. Forty-four heavily pretreated patients were entered on study. Forty were evaluable for toxicity and 36 for response as well. The maximum tolerated dosage of ifosfamide was 4.0 g/m2/d for 5 days (20 g/m2/course). Overall, 10 patients achieved complete remission, and 3 achieved partial remission. Remissions were brief, although four patients went on to bone marrow transplant while in remission. One patient is still alive. Conclusions. The combination of etoposide and ifosfamide with mesna uroprotection showed promising activity in children with multiply recurrent acute leukemia.",
keywords = "chemotherapy, etoposide, ifosfamide, pediatric oncology, recurrent acute leukemia",
author = "Bernstein, {M. L.} and Whitehead, {V. M.} and S. Devine and H. Grier and F. Kung and J. Krischer and Z. Dreyer and B. Bell and V. Land and Buchanan, {G. R.} and C. Pratt",
year = "1993",
language = "English (US)",
volume = "72",
pages = "1790--1794",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood

T2 - A Pediatric Oncology Group study

AU - Bernstein, M. L.

AU - Whitehead, V. M.

AU - Devine, S.

AU - Grier, H.

AU - Kung, F.

AU - Krischer, J.

AU - Dreyer, Z.

AU - Bell, B.

AU - Land, V.

AU - Buchanan, G. R.

AU - Pratt, C.

PY - 1993

Y1 - 1993

N2 - Background. Ifosfamide has previously been shown to be active as a single agent and in combination with doxorubicin, etoposide, and teniposide in pediatric solid tumors and adult acute leukemia. The authors performed a dose-escalation trial of ifosfamide with a fixed dosage of etoposide, with mesna uroprotection, in children with multiply recurrent acute leukemia. Methods. Chemotherapy was administered daily for 5 days. Etoposide 100 mg/m2 was followed by ifosfamide at an initial dosage of 1.6 g/m2. The ifosfamide was escalated in 20% increments to the maximum tolerated dosage in cohorts of three patients. Mesna 400 mg/m2 was given immediately before the ifosfamide and then at 3 and 6 hours after ifosfamide in the initial patients. Subsequent patients were treated with mesna 400 mg/m2 just before ifosfamide, and then every 2 hours to a total dosage equal to the ifosfamide dosage. Results. Forty-four heavily pretreated patients were entered on study. Forty were evaluable for toxicity and 36 for response as well. The maximum tolerated dosage of ifosfamide was 4.0 g/m2/d for 5 days (20 g/m2/course). Overall, 10 patients achieved complete remission, and 3 achieved partial remission. Remissions were brief, although four patients went on to bone marrow transplant while in remission. One patient is still alive. Conclusions. The combination of etoposide and ifosfamide with mesna uroprotection showed promising activity in children with multiply recurrent acute leukemia.

AB - Background. Ifosfamide has previously been shown to be active as a single agent and in combination with doxorubicin, etoposide, and teniposide in pediatric solid tumors and adult acute leukemia. The authors performed a dose-escalation trial of ifosfamide with a fixed dosage of etoposide, with mesna uroprotection, in children with multiply recurrent acute leukemia. Methods. Chemotherapy was administered daily for 5 days. Etoposide 100 mg/m2 was followed by ifosfamide at an initial dosage of 1.6 g/m2. The ifosfamide was escalated in 20% increments to the maximum tolerated dosage in cohorts of three patients. Mesna 400 mg/m2 was given immediately before the ifosfamide and then at 3 and 6 hours after ifosfamide in the initial patients. Subsequent patients were treated with mesna 400 mg/m2 just before ifosfamide, and then every 2 hours to a total dosage equal to the ifosfamide dosage. Results. Forty-four heavily pretreated patients were entered on study. Forty were evaluable for toxicity and 36 for response as well. The maximum tolerated dosage of ifosfamide was 4.0 g/m2/d for 5 days (20 g/m2/course). Overall, 10 patients achieved complete remission, and 3 achieved partial remission. Remissions were brief, although four patients went on to bone marrow transplant while in remission. One patient is still alive. Conclusions. The combination of etoposide and ifosfamide with mesna uroprotection showed promising activity in children with multiply recurrent acute leukemia.

KW - chemotherapy

KW - etoposide

KW - ifosfamide

KW - pediatric oncology

KW - recurrent acute leukemia

UR - http://www.scopus.com/inward/record.url?scp=0027185064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027185064&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 1790

EP - 1794

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -